From Bhamwiki
Jump to: navigation, search
BioCryst logo.png

BioCryst Pharmaceuticals Inc. (NASDAQ:BDRX) was a pharmaceutical research company founded in 1986 in Birmingham as a spin-off of UAB research. It went public in 1994 and moved its headquarters to Raleigh, North Carolina in 2010. It maintains a "Discovery Research Center and Laboratory Center of Excellence" in Birmingham.

Formerly headquartered at 2190 Parkway Lake Drive, BioCryst develops and manufactures various types of perscription drugs. Its two most well-known products include the influenza drug Peramivir, a treatment of T-cell mediated disorders called BCX-1777 and another treatment for T-cell mediated autoimmune diseases called BCX-4208.

BioCryst merged with Idera Pharmaceuticals of Exton, Pennsylvania in 2018.

Chief executives


BioCryst has developed several drug treatments:

  • Fodosine IV, for treatment of T-cell leukemia (Phase II/IIb)
  • Fodosine Oral, for treatment of cutaneous T-cell lymphoma (Phase I/II)
  • Fodosine Oral, for treatment of chronic lymphocytic leukemia (Phase I/II)
  • Fodosine IV, for treatment of B-cell acute lymphoblastic leukemia (Phase I/II)
  • BCX-4208 Oral, for treatment of autoimmune diseases/transplantation (Phase I)
  • Peramivir IV/IM, for treatment of seasonal/life-threatening influenza (Phase I)
  • BCX-4208 Oral, for treatment of Hepatitis C


External links